The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Current Best Practice in Hepatitis B Management & Understanding Long-Term Prospects for Cure
Gastroenterology. 2022 Oct 12;S0016-5085(22)01166-0.doi: 10.1053/j.gastro.2022.10.008. Online ahead of print.
1Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; Clinical Liver Diseases Fellow, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 10, Room 4-5722, 10 Center Drive, MSC 1800, Bethesda, MD 20892-1800. Electronic address: david.yardeni@nih.gov.
2Medical Research, Corporal Michael J. Crescenz VA Medical Center & Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Associate Chief of Staff and Associate Dean for Research, Corporal Michael J. Crescenz VA Medical Center and Professor of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104. Electronic address: kmchang@pennmedicine.upenn.edu.
3Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; Senior Investigator, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg 10, Room 9B-16, 10 Center Drive, MSC 1800, Bethesda, MD 20892-1800. Electronic address: marcg@intra.niddk.nih.gov.
Abstract
The hepatitis B virus (HBV) is a major cause of cirrhosis and hepatocellular carcinoma worldwide. Despite an effective vaccine the prevalence of chronic infection remains high. Current therapy is effective at achieving on-treatment but not off-treatment viral suppression. Loss of hepatitis B surface antigen (HBsAg), the best surrogate marker of off-treatment viral suppression, is associated with improved clinical outcomes. Unfortunately, this endpoint is rarely achieved with current therapy because of their lack of effect on covalently closed circular DNA, the template of viral transcription and genome replication. Major advancements in our understanding of HBV virology along with better understanding of immunopathogenesis have led to the development of a multitude of novel therapeutic approaches with the prospect of achieving functional cure (HBsAg loss) and perhaps complete cure (clearance of cccDNA and integrated HBV DNA). This review will cover current best practice for managing chronic HBV infection and emerging novel therapies for HBV infection and their prospect for cure.